Nephrocare Health Services working capital

·Pharma & HealthChart ›
ProfitabilityGrowthCreditLiquidityWorking capitalDividend yieldDuPontCAGR
Per cent unless marked ×
Tap a line for its trendFY26Mar 2026
53.17×
115.80×
230.16×
−61.19×
1.85×
0.68×
3.03×
1.02×
Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

NEPHROPLUS₹628.55

Nephrocare Health Services Limited

· Pharma & Health
₹ CrorePeersKRSNAASURAKSHAHEALTHX3BBLACKBIOMcap ₹6,307 Cr
ProfitabilityGrowthCreditLiquidityWorking CapitalYield AnalysisDuPont
Ratios — % unless marked ×
12 Months Ending
FY26
31/03/2026
Inventory Days (DIO)53.17
Receivable Days (DSO)115.80
Payable Days (DPO)230.16
Cash Conversion Cycle (days)-61.19
Working Capital Turnover1.85
Asset Turnover0.68
Cash Conversion (CFO/Net Income)3.03
CFO/EBITDA1.02
No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.